Skip to content

RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2017-08-14

What RESPIRERX PHARMACEUTICALS INC. reported in its quarterly report filed 2017-08-14 (fiscal Q2 2017): 21 published measures, 61 facts as tagged in accession 0001493152-17-009093.

This filing

Form
10-Q (quarterly report)
Filed
2017-08-14
Fiscal period
fiscal Q2 2017
Accession
0001493152-17-009093 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All RESPIRERX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-30190,691USD
At 2016-12-31233,847USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-06-30-6,309,336USD
At 2016-12-31-5,493,377USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-3030,848USD
At 2016-12-3192,040USD
At 2016-06-30347,256USD
At 2015-12-3153,199USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-1,584,066USD91
2017-01-01 to 2017-06-30-3,053,212USD181
2016-01-01 to 2016-12-31-9,229,760USD366
2016-04-01 to 2016-06-30-2,731,249USD91
2016-01-01 to 2016-06-30-5,412,200USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-456,393USD181
2016-01-01 to 2016-12-31-1,328,684USD366
2016-01-01 to 2016-06-30-867,898USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-01-01 to 2017-06-30395,201USD181
2016-01-01 to 2016-06-301,161,955USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-160,563,991USD
At 2016-12-31-157,510,779USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-06-301,884USD
At 2016-12-315,167USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-1,549,517USD91
2017-01-01 to 2017-06-30-2,970,203USD181
2016-04-01 to 2016-06-30-2,349,525USD91
2016-01-01 to 2016-06-30-4,766,301USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-30163,276USD
At 2016-12-31195,676USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-04-01 to 2017-06-3026,283USD91
2017-01-01 to 2017-06-3051,321USD181
2016-04-01 to 2016-06-30199,441USD91
2016-01-01 to 2016-06-30446,206USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-306,500,027USD
At 2016-12-315,727,224USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-04-01 to 2017-06-301,549,517USD91
2017-01-01 to 2017-06-302,970,203USD181
2016-04-01 to 2016-06-302,349,525USD91
2016-01-01 to 2016-06-304,766,301USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2017-06-30631,200USD91
2017-01-01 to 2017-06-301,062,010USD181
2016-04-01 to 2016-06-30926,920USD91
2016-01-01 to 2016-06-301,844,056USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-302,289,045shares
At 2016-12-312,149,045shares
At 2012-08-10443,205shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-06-30154,230,663USD
At 2016-12-31151,993,550USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-06-3019,013USD
At 2016-12-3115,730USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-1,584,066USD91
2017-01-01 to 2017-06-30-3,053,212USD181
2016-04-01 to 2016-06-30-2,731,433USD91
2016-01-01 to 2016-06-30-5,413,365USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30918,317USD91
2017-01-01 to 2017-06-301,908,193USD181
2016-04-01 to 2016-06-301,422,605USD91
2016-01-01 to 2016-06-302,922,245USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-06-303,283USD181
2016-01-01 to 2016-06-303,477USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-01-01 to 2017-06-30350,000USD181
2016-01-01 to 2016-06-30309,985USD182

Inspect the source

Entity
RESPIRERX PHARMACEUTICALS INC. / CIK 0000849636
Captured
SEC response SHA-256
f692532c7d166963e2fad68da28689f5b935e4c0402c22ccfa62bc8615c926ab

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000849636.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))